Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
I421566-1ml
|
1ml |
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
|
$241.90
|
|
AMPK Activators
| Synonyms | 1422365-93-2 | HL-156A free base | IM156 | UNII-4G3BUV6ZSK | IM156 free base | HL156A free base | IM-156 free base | Lixumistat | 4G3BUV6ZSK | HL271 | N-(N-(4-(Trifluoromethoxy)phenyl)carbamimidoyl)pyrrolidine-1-carboximidamide | N-(Imino((4-(trifluoromethoxy)phenyl)amino)meth |
|---|---|
| Specifications & Purity | 10mM in DMSO |
| Biochemical and Physiological Mechanisms | IM156 (HL156A), a metformin derivative, is a potent activator of AMPK that increases AMPK phosphorylation. IM156 blocks oxidative phosphorylation (OXPHOS) through the inhibition of complex I and increases apoptosis. IM156 ameliorates various types of fibr |
| Storage Temp | Store at -80°C |
| Shipped In |
Ice chest + Ice pads This product requires cold chain shipping. Ground and other economy services are not available. |
| Product Description |
Information IM156 IM156 (HL156A), a metformin derivative, is a potent activator of AMPK that increases AMPK phosphorylation. IM156 blocks oxidative phosphorylation (OXPHOS) through the inhibition of complex I and increases apoptosis . IM156 ameliorates various types of fibrosis and inhibits tumors. Targets AMPK ; OXPHOS In vitro IM156 (HL156A) treatment of RPMCs inhibits HG-induced myofibroblast transdifferentiation and markers of epithelial-mesenchymal transition (EMT). Moreover, IM156 (HL156A) ameliorates HG-induced transforming growth factor-β1, Smad3, Snail, and fibronectin expression in the RPMCs via AMPK upregulation. IM156 treatment decreases complex I-dependent NADH oxidation in a significant, dose-dependent manner. In vivo In vivo treatment of IM156 exacerbated the memory differentiation of virus-specific CD8+ T cells results in an increase in short-lived effector cells but decrease in memory precursor effector cells. Thus, IM156 treatment impaires the function of virus-specific memory CD8+ T cells, indicating that excessive AMPK activation weakens memory T cell differentiation, thereby suppressing recall immune responses. Cell Research(from reference) Cell lines:Rat peritoneal mesothelial cells (RPMCs) Concentrations:10 μM, 30 μM, 50 μM Incubation Time:24 h |
Taxonomy Tree
| Kingdom | Organic compounds |
|---|---|
| Superclass | Benzenoids |
| Class | Phenol ethers |
| Subclass | Not available |
| Intermediate Tree Nodes | Not available |
| Direct Parent | Phenol ethers |
| Alternative Parents | Phenoxy compounds Biguanides Pyrrolidines Trihalomethanes Propargyl-type 1,3-dipolar organic compounds Carboximidamides Azacyclic compounds Organooxygen compounds Organofluorides Imines Hydrocarbon derivatives Alkyl fluorides |
| Molecular Framework | Aromatic heteromonocyclic compounds |
| Substituents | Phenoxy compound - Phenol ether - Biguanide - Monocyclic benzene moiety - Pyrrolidine - Trihalomethane - Guanidine - Azacycle - Organoheterocyclic compound - Organic 1,3-dipolar compound - Propargyl-type 1,3-dipolar organic compound - Carboximidamide - Alkyl fluoride - Hydrocarbon derivative - Organooxygen compound - Organonitrogen compound - Organofluoride - Organohalogen compound - Imine - Halomethane - Organic oxygen compound - Organic nitrogen compound - Alkyl halide - Aromatic heteromonocyclic compound |
| Description | This compound belongs to the class of organic compounds known as phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring. |
| External Descriptors | Not available |
|
|
|
| ALogP | 3.622 |
|---|---|
| HBD Count | 2 |
| Rotatable Bond | 7 |
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
| IUPAC Name | N'-[N'-[4-(trifluoromethoxy)phenyl]carbamimidoyl]pyrrolidine-1-carboximidamide |
|---|---|
| INCHI | InChI=1S/C13H16F3N5O/c14-13(15,16)22-10-5-3-9(4-6-10)19-11(17)20-12(18)21-7-1-2-8-21/h3-6H,1-2,7-8H2,(H4,17,18,19,20) |
| InChIKey | NGFUHJWVBKTNOE-UHFFFAOYSA-N |
| Smiles | C1CCN(C1)C(=NC(=NC2=CC=C(C=C2)OC(F)(F)F)N)N |
| Isomeric SMILES | C1CCN(C1)/C(=N/C(=NC2=CC=C(C=C2)OC(F)(F)F)N)/N |
| PubChem CID | 71512108 |
| Molecular Weight | 315.29 |
| DMSO(mg / mL) Max Solubility | 63 |
|---|---|
| DMSO(mM) Max Solubility | 199.816042373688 |
| Water(mg / mL) Max Solubility | <1 |
| Molecular Weight | 315.290 g/mol |
| XLogP3 | 2.100 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 4 |
| Exact Mass | 315.131 Da |
| Monoisotopic Mass | 315.131 Da |
| Topological Polar Surface Area | 89.200 Ų |
| Heavy Atom Count | 22 |
| Formal Charge | 0 |
| Complexity | 424.000 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| The total count of all stereochemical bonds | 1 |
| Covalently-Bonded Unit Count | 1 |